![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, January 18, 2018 11:01:10 AM
http://ascopubs.org/doi/full/10.1200/JOP.2017.023333
"Breast cancer is the most frequent tumor worldwide, and approximately 255,000 women will be diagnosed with breast cancer in the United States in 2017. Approximately 10% to 20% of these patients will be diagnosed with [triple-negative breast cancers or TNBC]"
"...[TNBCs] present with a varied natural history but are collectively associated with poor prognosis with high risk of relapse and short progression-free survival (PFS) and overall survival (OS). As many as 50% of patients diagnosed with early-stage TNBC (stages I to III) experience disease recurrence, and 37% die in the first 5 years after surgery."
"...indicating the pressing need for drug development for treating [TNBC]."
"Finally, immune therapy has gained unprecedented momentum with checkpoint inhibitors that show significant efficacy and favorable toxicity profile for the treatment of solid tumors. [TNBC] is thought to have a high frequency of genomic alteration and neoantigen formation. Pembrolizumab [Keytruda], however, which is a monoclonal anti-programmed cell death protein 1 (PD-1) antibody was tested in a phase Ib trial of 32 patients with programmed death ligand 1 (PD-L1)–positive [TNBC] and showed a modest response rate of 18.5%. Investigational strategies, including the combination of different checkpoint inhibitors and the development of antibody-drug conjugates, are ongoing."
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM